BTG NEWS 2024 EDITION, ISSUE 2

EGENERATION TO END THE AIDS EPIDEMIC

FROM THE EDITOR

Same newsletter, new editor! As the new editor I'm thinking about what Be the Generation means to me. I think of the generations before - the people who experienced the HIV epidemic from the beginning and those who have spent decades continuing their tireless efforts to end the epidemic. I also think of future generations and the dream that they will be unaffected by HIV. And here we are in between, in the present, with the potential to Be the Generation to end the epidemic.

The overlap between generations reminds me of the interconnectedness of us all, which in turn reminds me that, to end the epidemic, we will require a responsibility to each other. I see that responsibility demonstrated by people who participate in trials to benefit others, by individuals who represent their communities on community advisory boards, and by you, the readers of this newsletter, as you participate in this effort and spread the word.

That responsibility is reflected all over this issue of BTG News, including in the Networks' news of awards presented to dedicated CAB members and advocates, tireless social justice and human rights work by advocates and organizations in the HIV space, and a call for advocates, allies, community partners, and clinical research staff and investigators to come together to learn and share about HIV prevention. Read on to learn about each of these and more, and thanks for staying engaged and working together to Be the Generation.


Cat Banobi, Project Manager & The Legacy Project

KEEP IN TOUCH

Email us at btg@hanc.info & Follow the Legacy Project at:



f Legacy Project





NETWORK NEWS HIV PREVENTION TRIALS NETWORK (HPTN)



HPTN Annual Meeting - Don't Miss Out!

The 2024 HPTN Annual Meeting will be held at the JW Marriott in Washington, D.C., from June 14–18. A remote option is available for those who cannot attend or choose not to participate in person.



The meeting will feature several plenaries, presentations, discussions regarding HIV prevention and intersecting research, question-and-answer sessions, and study-specific protocol team meetings.

Registration Options

All registered attendees will have access to the virtual Attendee Hub platform via desktop or mobile app. When starting the online registration process, select one of the following registration types based on your intended participation:

- **Hybrid** Select this option if you plan on attending in person for at least one day. Upon check-in, you will receive a printed badge, agenda book, other materials, and full access to the virtual Attendee Hub.
- **Remote** Select this option if you do not plan on joining us in Washington, D.C. You will have full access to the virtual Attendee Hub to view live plenaries and participate in virtual sessions.

Who Should Attend?

- Clinical Trial Units (CTUs)/Clinical Research Sites (CRS) staff
 - Principal Investigators/Investigators of Record
 - Key study staff (community representative, community educators, study coordinators, study clinicians/nurses, laboratory representative, pharmacists)
- Investigators engaged in HIV prevention research
- Advocates, allies, and community partners supporting HIV prevention efforts

Note: The HPTN Leadership and Operations Center (LOC) has provided all supported travelers with a unique registration link. Please <u>email</u> us if you are still waiting to receive the link.

REGISTER

NETWORK NEWS HIV VACCINE TRIALS NETWORK (HVTN)



At our annual Full Group Meeting (May 1-3, 2024), the HVTN recognized several community members with awards for their passion and dedication to HIV education, prevention, and research.



The Octavio Valente, Jr. Volunteer Service Award is given to a Community Advisory Board (CAB) member who has demonstrated exemplary leadership and dedication in the HVTN. It is named in honor of Octavio Valente, Jr., a dedicated CAB member who passed away in 2006. He directed his advocacy and spirited energy to many roles in the HVTN and in the HIV prevention community in Brazil. This year's award recipient is **Hala Fawal**, a CAB member at the University of Alabama-Birmingham (UAB) Clinical Research Site. She is an esteemed member of the local CAB at UAB, represents UAB on the Global CAB, and lends her voice as the community representative on the HVTN's Network Evaluation Committee.

The Wakefield Outstanding Dedication Award is named in honor of former HVTN External Relations Director Steve Wakefield for his decades of exemplary service; it recognizes the recipients' steadfast passion for HIV research, shaping HIV vaccine education and research efforts. This year's Latin America award recipient is **ABIA** (Associação Brasileira Interdisciplinar de AIDS/ Observatório Nacional de Políticas de AIDS). Since 2015, The National AIDS Policy Observatory, an initiative of the Brazilian Interdisciplinary AIDS Association (ABIA), has strengthened social and human rights to influence public policies to combat the HIV epidemic.

This year's United States recipient of the Wakefield Award is **Dr. Dázon Dixon Diallo.** Dr. Diallo is founder and president of SisterLove, Inc. She is a visionary and advocate in the effort for human rights, sexual and reproductive justice, and in the HIV response with and on behalf of people, especially women and girls, living with and without HIV in communities that are most affected by HIV and STIs. She is also a proud member of In Our Own Voice: National Black Women's Reproductive Justice Agenda Partnership, where she advocates for sexual and reproductive health, rights and justice in public health, and prevention policies and programs.



NETWORK NEWS HIV VACCINE TRIALS NETWORK (HVTN)



The HVTN Research and Mentorship Program (RAMP) has accepted 11 scholars for Cohort 14! Scholars will be working with mentors on projects at Clinical Research Sites in:

The US: Los Angeles, New York, and Rochester

Malawi: Blantyre

South Africa: Isipingo, Klerksdorp, Rustenburg, and Soshanguve

Zambia: Lusaka

Welcome Cohort 14 RAMP Scholars! Welcome Cohort 14 RAMP Scholars!

To learn more about our scholars and the projects they will be working on, please visit the <u>RAMP Scholar Profiles</u>.



We are thrilled to share results from two IMPAACT studies that were recently presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), held from March 3-6, 2024 in Denver, Colorado:

<u>Children Surpass a Year of HIV Remission after Treatment Pause</u>

Four children have remained free of detectable HIV for more than one year after their antiretroviral therapy (ART) was paused to see if they could experience HIV remission. The children, who acquired HIV before birth, were closely monitored in IMPAACT P1115 for safety and HIV viral suppression. Read the full press release here.

Why is this important? Scientists are hopeful that ART started shortly after birth may help make it possible for children to control HIV in their bodies eventually without ART. These results indicate that more scientific research is necessary to understand HIV remission and the role of early ART in children living with HIV.

Long-Acting HIV Treatment Benefits Adolescents with Suppressed HIV

Long-acting, injectable ART was found to be safe in adolescents with HIV viral suppression in IMPAACT 2017 (MOCHA). In addition, drug levels in adolescents were found to be comparable to levels observed in adults. Read the full press release here.

Why is this important? Before these results, scientists understood that long-acting injectable ART was safe and effective for adults. These results demonstrate that it is a viable alternative to daily oral ART for adolescents (aged 12 to 17) as well.

Stay connected! Follow the IMPAACT Network on Facebook, X (formerly Twitter), and LinkedIn (@IMPAACTNetwork). Visit our website to learn more and subscribe to our <u>quarterly newsletter.</u>

HANC RESOURCES



RESOURCES

Be the Generation website: the best place to go for trustworthy information on biomedical HIV prevention research. Features sections on PrEP, U=U, Microbicides, HIV vaccine research, inspiring videos from researchers and community members, and even a quiz to test your knowledge of HIV prevention research.

The <u>H=H Podcast</u>: The podcast that centers on the 'Human' in 'HIV.' This podcast is sponsored by the HANC Legacy Project and presents content on the human side of research, featuring scientists, community members, and affirming communities disproportionately affected by HIV.

Webinar Library: a collection of over 30 of our webinar recordings on topics such as Monkeypox, HIV & race, HIV & women, HIV genetic sequencing, HIV & aging, outreach & marketing, Native Americans & HIV, microbicides research, pregnancy & lactation in HIV research, HIV in the Latinx community, community engagement, and more.

Transgender Training Resources Homepage: the Division of AIDS at the National Institute of Allergy and Infectious Diseases has put all its amazing resources related to research with transgender communities in one place. All resources are free; you may just need to create a free account if you don't have one already.

IMPORTANT DATES

June 5: HIV Long-Term Survivors Awareness Day

June 8: National Caribbean American HIV/AIDS Awareness Day

June 12-15: ACTG Annual Meeting in Washington, DC and virtually

June 14-18: HPTN Annual Meeting in Washington, DC and virtually

June 19: Juneteenth

June 27: National HIV Testing Day

July 14: International Non-Binary People's Day

July 21: Zero HIV Stigma Day

August 20: Southern HIV/AIDS Awareness Day

August 29: National Faith HIV/AIDS Awareness Day

September 12-15: US Conference on HIV/AIDS September 22-27: IMPAACT Network Meeting